title: Neutralization of HIV-1 by anti-idiotypes to monoclonal anti-CD4. Potential for idiotype immunization against HIV.
abstract: Anti-idiotypic antibodies were raised in rabbits against a panel of 11 murine mAb directed to the human CD4 receptor. Selection of mAb for vaccination was based on inhibition studies demonstrating that these mAb recognized CD4/V1 epitopes implicated in HIV-1-gp120 binding. Purified antisera showed high titer anti-Id activity and reacted specifically with Ag-combining site-related Id of the mAb used for their generation. Anti-Id either detected a private Id of the immunizing mAb or displayed a partial cross-reactivity with Id of other mAb to CD4. Eight anti-Id to six different mAb were shown to recognize determinants of recombinant HIV-1-gp120 or of HIV-1-gp160 as shown by ELISA and radioimmunoprecipitation assay. These anti-Id were capable of inhibiting HIV infection up to 100% in a MT-4 cell assay in vitro. In addition to neutralizing infectivity of cell-free virus, anti-Id to two mAb--the mAb IOT4a and 7.3F11--were also shown to inhibit HIV-induced syncytia formation up to 100%. Anti-Id to the mAb IOT4a, 7.3F11, and to the mAb anti-Leu3a interfered with rgp120 binding to cellular CD4 as assessed by flow cytometry. These results demonstrated that mAb specific for both CDR2- and CDR3-like regions of CD4 were capable of inducing HIV-1-gp120 cross-reacting anti-Id neutralizing HIV-1 in vitro. These studies may have implications for the development of a gp120 internal image based vaccine against HIV.
authors.affiliation: Department of Internal Medicine, Medical School of Hannover, Germany.
authors.forename: G C
authors.initials: GC
authors.lastname: Sutor
authors.forename: U
authors.initials: U
authors.lastname: Dreikhausen
authors.forename: U
authors.initials: U
authors.lastname: Vähning
authors.forename: E
authors.initials: E
authors.lastname: Jurkiewicz
authors.forename: G
authors.initials: G
authors.lastname: Hunsmann
authors.forename: K
authors.initials: K
authors.lastname: Lundin
authors.forename: I
authors.initials: I
authors.lastname: Schedel
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology; D001667:Binding, Competitive; D015704:CD4 Antigens / Q000276:immunology*; D003429:Cross Reactions; D015686:Gene Products, env / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D019302:HIV Envelope Protein gp160; D015497:HIV-1 / Q000276:immunology*; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D051379:Mice; D009500:Neutralization Tests; D011498:Protein Precursors / Q000276:immunology; D011817:Rabbits
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D015686:Gene Products, env; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D007130:Immunoglobulin Idiotypes; D011498:Protein Precursors